Company profile

Innovent Biologics

Diversified biologics

1801 · HKEX · China

Public Market Listing

1801HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Innovent Biologics are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(13 total)

13Total Assets

2Approved

6Phase 3 / Filed

5Phase 1–2 / Early

9Diseases

Showing 13 of 13 assets

		Target & Modality
Equecabtagene autoleucel	Approved	BCMACell therapy	Multiple Myeloma
Tafolecimab(Sintbilo)	Approved	PCSK9Monoclonal antibody	Atherosclerotic Cardiovascular Disease
Fulzerasib	Phase 3	KRAS G12CSmall molecule	Non-Small Cell Lung Cancer
IBI3003	Phase 3	GPRC5D x BCMA x CD3Multispecific antibody	Multiple Myeloma
IBI305	Phase 3	VEGFMonoclonal antibody	Non-Small Cell Lung Cancer
mazdutide	Phase 3	GLP-1/glucagon receptor (dual)Peptide	ObesityType 2 Diabetes
picankibart	Phase 3	IL-23 p19Monoclonal antibody	Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis
Sintilimab	Phase 3	PD-1Monoclonal antibody	Non-Small Cell Lung Cancer
IBI3016	Phase 2	Angiotensinogen (AGT)RNA / oligonucleotide	Hypertension
IBI356	Phase 2	OX40LMonoclonal antibody	Atopic Dermatitis
IBI363	Phase 2	PD-1 x IL-2Rα (IL2RA)Multispecific antibody	Non-Small Cell Lung Cancer
IBI3032	Phase 1	GLP-1 receptorSmall molecule	Obesity
IBI3033	Phase 1	Undisclosed / early pipeline	Atopic Dermatitis

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.